Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda
| Autor: | Sylvia Kusemererwa, Martin Onyango, Joseph Mugisha, Anita Kabarambi, Andrew Abaasa |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty Anti-HIV Agents Epidemiology Sexual Behavior Dapivirine Human immunodeficiency virus (HIV) HIV Infections Dermatology medicine.disease_cause Placebo Young Adult 03 medical and health sciences 0302 clinical medicine Risk Factors Microbicide medicine Humans 030212 general & internal medicine 030505 public health Vaginal microbicide business.industry Obstetrics sexual behaviour Contraceptive Devices Female HIV Vaginal ring Risk compensation Pyrimidines Infectious Diseases vaginal microbicides Female Trichomonas vaginalis women 0305 other medical science business |
| Zdroj: | Sexually Transmitted Infections |
| ISSN: | 1472-3263 1368-4973 |
| DOI: | 10.1136/sextrans-2020-054718 |
| Popis: | ObjectivesParticipation in HIV prevention trials could trigger risk compensation among participants. We evaluated potential risk compensation following use of a vaginal ring microbicide by women in a phase III trial in southwestern Uganda.MethodsWe used markers of sexual risk behaviour documented on standardised questionnaires, tested for STIs at baseline and quarterly for 2 years. Risk compensation was defined as a significant increase (trend pResultsBetween September 2013 and December 2016, 197 women (active arm: n=132 and placebo: n=65) were enrolled at the Masaka site. There were decreases in all markers of sexual risk behaviour with statistically significant decreases in only the proportion of women reporting ≥2 sexual partners, p=0.026 and those diagnosed with Trichomonas vaginalis pNeisseria gonorrhoeae pConclusionsNo evidence of risk compensation was observed in this trial.Trial registration numberNCT01539226. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|